Expert Illustrations & Commentaries: Visualizing Therapies on the Horizon for Presbyopia

Released On
September 17, 2021

Expires On
September 17, 2022

Media Type

Completion Time
60 minutes

Ophthalmology, Optometry

Eye Disorders, Presbyopia

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.


This activity is supported by an educational grant from AbbVie

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Optometrists — 1.0 COPE credit(s)
  • Nurses — 1.0 Contact Hour

All other healthcare professionals completing this course will be issued a statement of participation. For those seeking COPE credit on this topic, please click here: for this program.

Target Audience

This educational activity is directed toward ophthalmologists and optometrists, including those in residency and fellowship training. Other clinicians involved in the care of patients suffering from presbyopia are also invited to participate.

Program Overview

This Expert Illustrations and Commentaries™ is a video-based program in which 2 experts discuss the etiology and management of presbyopia. In this activity, the faculty focus on the pathophysiology and current and emerging therapeutic strategies for the management of presbyopia. Their discussion is enriched with the use of video animation to illustrate the pathophysiology of presbyopia and the mechanism of action of a new therapies. The use of these animated segments helps make somewhat complicated subject matter more easily understood. This unique format is designed to help clinicians identify best practices in the diagnosis and management of presbyopia and to improve outcomes for their patients with this disease.

An estimated 110 million people in the United States have presbyopia. It is the most common visual impairment of the “baby boomer” generation (born between 1946 and 1964). Despite the prevalence of presbyopia, even in developed countries, around one-third of presbyopia remains untreated. If left uncorrected, presbyopia can affect both quality of vision and quality of life. Presbyopia can inhibit a person’s ability to perform tasks at a customary working distance without experiencing visual symptoms, even if those tasks were once performed effortlessly. If presbyopia is going to occur, it typically begins after age 40 and is progressive until around 65 years, when near focusing can be completely lost.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Discuss the pathophysiology of presbyopia as related to loss of accommodation
  • Summarize current approaches to the treatment of presbyopia
  • Describe the mechanisms of action for novel topical therapies for presbyopia
  • Evaluate the efficacy and safety of emerging, investigational topical therapies for presbyopia



Francis S. Mah, MD

Director of Cornea Service
Co-Director of Refractive Surgery Service
Division of Ophthalmology
Department of Surgery
Scripps Clinic
La Jolla, CA


Selina R. McGee, OD, FAAO

Founder/CEO of BeSpoke Vision
Adjunct Faculty Northeastern State University Oklahoma College of Optometry (NSUOCO)
BeSpoke Vision
Edmond, OK

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

This activity, COPE Activity Number 122352, is accredited by COPE for continuing education for optometrists.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

Francis S. Mah, MD

  • Consultant: Allergan, Novartis, Ocular Science

Selina R. McGee, OD, FAAO

  • Consultant: Allergan, Lumenis, Cynosure, Horizon, Optovue, Novartis, Sun, Versant, Kala, Novartis, Dompe, Osmotica, Tarsus

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.